First author (publication year) | No of patients | Group | Regimens | Duration of treatment (week) |
---|---|---|---|---|
Özdoğan (2020) | 93 | SOF/LDV | NA | 12 |
28 | PTVr/OBV + DSV | 12 | ||
Inoue (2018) | 85 | SOF/LDV | Harvoni® (SOF 400 mg + LDV 90 mg) QD | 12 |
46 | SOF/RBV | Sovaldi® (SOF) 400 mg QD + Rebetol® (RBV) 600/800/1000 mg (depending on body weight) BID | 12 | |
85 | ASV/DCV | Dacluinza® (DCV) 60 mg QD + Sunbepra® (ASV) 100 mg BID | 24 | |
Endo (2017) | 132 | SOF/LDV | Harvoni® (SOF 400 mg + LDV 90 mg) QD | 12 |
121 | ASV/DCV | Dacluinza® (DCV) 60 mg QD + Sunbepra® (ASV) 100 mg BID | 24 | |
Kan (2017) | 55 | SOF/LDV | Harvoni® (SOF 400 mg + LDV 90 mg) QD | 12 |
40 | PTVr/OBV | Viekirax® (PTVr 150/100 mg + OBV 25 mg) QD | 12 | |
Notsumata (2017) | 140 | SOF/LDV | NA | 12 |
100 | SOF/RBV | 12 | ||
173 | ASV/DCV | 24 | ||
50 | PTVr/OBV | 12 | ||
Hashimoto (2016) | 76 | SOF/LDV | Harvoni® (SOF 400 mg + LDV 90 mg) QD | 12 |
24 | ASV/DCV | ASV 100 mg + DCV 60 mg BID | 24 |